#TSP TruSpine Technologies PLC – Convertible Loan Note Conversion & Issue of Equity June 5, 2024 – Posted in: TruSpine Plc (TSP) – Tags: capital, instrument, regulation, resolutions, rights, shares, stabilisation, stocks, subscription, TSP, voting
TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that, further to the announcement on 26 March 2024, the Company has elected to convert the Lender CLN Subscription of £200,000 into 13,333,333 new ordinary shares at a price of 1.5 pence per share (“CLN Shares”) pursuant to the terms of the CLN Instrument.
Admission
Application has been made for the CLN Shares to be admitted to trading on the Aquis Stock Exchange Growth Market on or around 11 June 2024 (“Admission”), subject to certain resolutions being passed at the Company’s forthcoming annual general meeting to be held on 7 June 2024, and will rank pari passu with the ordinary shares of the Company in issue.
Total Voting Rights
Following Admission, the Company’s issued share capital will consist of 153,027,900 ordinary shares with voting rights. The new ordinary shares will rank pari passu with the existing ordinary shares. No ordinary shares are held in treasury at the date of this announcement and therefore following Admission, the total number of ordinary shares in the Company with voting rights will be 153,027,900.
This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Company’s announcement of 26 March 2024.
Enquiries:
|
TruSpine Technologies Plc |
Tel: +44 (0)20 7118 0852 |
|
Geoff Miller, Non-executive Chairman |
|
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser) |
Tel: +44 (0)20 7213 0880 |
|
Liam Murray / Ludovico Lazzaretti |
|
|
Peterhouse Capital Limited (Broker & Financial Adviser) |
|
|
Lucy Williams / Duncan Vasey
|
|
|
Novus Communications (PR and IR) |
Tel: +44 (0)207 448 9839 |
|
Alan Green / Jacqueline Briscoe |